Item 7.01 Regulation FD Disclosure.

On June 23, 2021, VBI Vaccines Inc. (the "Company") issued a press release announcing the final results from a Phase 1b/2a study of BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Company undertakes no obligation to update, supplement or amend the materials attached hereto.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished pursuant to Item 7.01 and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.   Description

99.1            Press Release, dated June 23, 2021 (furnished pursuant to Item
              7.01)
104           Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses